Long-term treatment outcome of type 1 thyroplasty using novel titanium medialization laryngoplasty implant combined with arytenoid adduction for unilateral vocal cord paralysis: single-arm interventional study at a single institution

Daisuke Sano MD, PhD1 | Koji Matsushima MD, PhD2 | Yasuhiro Isono MD, PhD3 | Yukiko Ikui PhD | Yuri Kinutani BA1 | Yoshihiro Chiba MD1 | Hajime Hirose MD, PhD1 | Nobuhiko Oridate MD, PhD1

1Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, School of Medicine, Yokohama, Japan
2Department of Otolaryngology, Toho University Omori Medical Center, Tokyo, Japan
3Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University Medical Center, Yokohama, Japan

Correspondence
Daisuke Sano, MD, PhD, Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, School of Medicine, 3-9 Fukaura, Kanazawa-ku, Yokohama 236-0004, Japan.
Email: dsano@yokohama-cu.ac.jp

Funding information
Yokohama City University Hospital

Abstract
Objective: To evaluate the long-term treatment outcome of type 1 thyroplasty with novel rearrangeable titanium medialization laryngoplasty implant (TMLI) combined with arytenoid adduction (AA) for unilateral vocal cord paralysis (UVFP) in the authors’ institution.

Methods: A total of 16 Japanese patients with UVFP who received type 1 thyroplasty using TMLI with arytenoid adduction was enrolled in this single-arm, non-randomized interventional study. The results of the auditory perceptual assessment, aerodynamic examination, acoustic measurement, and patient-based survey on these patients were evaluated preoperatively and at 3, 6, and 12 months postoperatively.

Results: Type 1 thyroplasty using TMLI with arytenoid adduction for our patient series presented significant improvements in maximum phonation time, mean flow rates, GRBAS scale, the Voice Handicap Index and the Voice-Related Quality of Life score over the 12-month postoperative period.

Conclusion: Type 1 thyroplasty using TMLI with arytenoid adduction was quite effective for obtaining satisfactory postoperative voice improvement without any surgical complication over the long-term period.

KEYWORDS
arytenoid adduction, titanium medialization laryngoplasty implant, type 1 thyroplasty, unilateral vocal fold paralysis

1 | INTRODUCTION

Unilateral vocal fold paralysis (UVFP) with the paralyzed vocal fold fixed at the paramedian or intermediate position usually causes deficient glottic closure resulting in dysphonia, dysphagia, or shortness of breath during physical activity, which may impact on the patient’s quality of life. Furthermore, the bowing of the paralyzed vocal fold margin, the level difference between both vocal folds...
Titanium is one of other major materials for type 1 thyroplasty, as reported previously as titanium vocal fold medialization implant (TVFMI). This metallic material is widely used as medical devices, such as dental applications, and surgical implants for orthopedic surgical procedure due to its high strength-to-weight, corrosion resistance, and tissue affinity. In fact, the significance of the long-term functional outcomes of type I or II thyroplasty using titanium implants was reported by Schneider-Stickler and Sanuki et al, respectively. However, there is no surgical equipment for type I thyroplasty officially approved by Japanese Ministry of Health, Labor and Welfare at present.

We therefore have developed novel titanium medialization laryngoplasty implant (TMLI) for type 1 thyroplasty combined with arytenoid adduction (AA) for the purpose of the reproduction of sufficient vocal fold function in patients with UVFP. We then conducted a prospective clinical trial to evaluate the long-term treatment outcome of type 1 thyroplasty with our novel rearrangeable TMLI combined with AA for UVFP.

### TABLE 1 Clinical characteristics

| Patient | Sex | Age | Side | Cause of unilateral vocal cord paralysis | Duration till thyroplasty (mo) | Preoperative GRABS scale | Preoperative MPT (s) | Size of titanium implant (mm) |
|---------|-----|-----|------|------------------------------------------|-----------------------------|--------------------------|----------------------|-----------------------------|
| 1       | M   | 62  | L    | Idiopathic                               | 9                          | G3R1B3A0S0               | 2.00                 | 3 × 10 × 2                |
| 2       | M   | 54  | L    | Post carotid surgery (tetralogy of Fallot) | 540                        | G3R1B3A0S0               | 7.66                 | 2.5 × 10 × 4              |
| 3       | M   | 68  | L    | Post carotid surgery (aneurysm of the thoracic aorta) | 9                          | G3R2B3A1S0               | 3.05                 | 4 × 10 × 5                |
| 4       | F   | 70  | L    | Post thyroidectomy (thyroid cancer)       | 32                         | G2R2B2A0S0               | 8.31                 | 3.5 × 7 × 3               |
| 5       | F   | 21  | L    | Post thyroidectomy (thyroid cancer)       | 5                          | G2R2B2A0S0               | 9.93                 | 1 × 8 × 1                 |
| 6       | F   | 45  | R    | Idiopathic                               | 60                         | G2R1B2A2S0               | 10.03                | 3 × 10 × 2                |
| 7       | M   | 25  | L    | Post surgery (jugular foramen tumor)      | 54                         | G2R2B2A0S0               | 5.83                 | 3 × 10 × 5                |
| 8       | F   | 77  | L    | Post surgery (lung cancer)                | 21                         | G3R1B3A2S0               | 5.13                 | 4 × 8 × 6                 |
| 9       | M   | 68  | L    | Post carotid surgery (aortic dissection)  | 4                          | G3R3B3A0S0               | 2.90                 | 4 × 10 × 5                |
| 10      | M   | 71  | R    | Post surgery (parathyroid cancer)         | 39                         | G3R3B3A0S0               | 2.96                 | 3 × 10 × 7                |
| 11      | M   | 74  | L    | Post surgery (esophageal cancer)          | 13                         | G3R3B3A0S0               | 5.69                 | 4 × 10 × 6                |
| 12      | M   | 46  | L    | Post surgery (esophageal cancer)          | 12                         | G2R1B2A0S0               | 5.68                 | 3 × 10 × 7                |
| 13      | M   | 65  | L    | Post surgery (lung cancer)                | 10                         | G3R0B3A0S0               | 2.53                 | 3 × 10 × 9                |
| 14      | M   | 61  | L    | Post surgery (esophageal cancer)          | 24                         | G2R2B2A0S0               | 4.84                 | 3 × 10 × 5                |
| 15      | M   | 74  | L    | Post carotid surgery (aortic dissection)  | 8                          | G2R1B2A0S0               | 2.73                 | 5 × 9 × 8                 |
| 16      | F   | 49  | L    | Post thyroidectomy (thyroid cancer)       | 24                         | G2R1B2A1S0               | 3.75                 | 2 × 7 × 1                 |

2 | MATERIALS AND METHODS

2.1 | Study design and patients

This prospective single-arm intervention study was conducted between February 2016 and January 2020 at Yokohama City University Hospital, Yokohama, Japan. A total of 16 Japanese patients with UVFP for the duration more than 6 months was enrolled. The etiology of UVFP was shown in Table 1 (post-surgery in 14 patients including post-carotid surgery in 4 and post-thyroidectomy in 3, and idiopathic in 2). There were no patients who had received any injection laryngoplasty, previously. The primary endpoint of this trial was the improvement in maximum phonation time (MPT). The secondary endpoints included the improvement in auditory perceptual assessment.
aerodynamic parameters except MPT, acoustic parameters when possible, and patients’ subjective evaluation of own postoperative voice. Computed tomography at 6 months postoperatively was also conducted to assure the stable placement of the titanium implant. All patients provided written informed consent and the protocol of the present study was reviewed and approved by the institutional review boards of our institution (approval IDs: B151203007, UMIN ID 000020616). Fourteen patients out of the 16 were evaluated preoperatively and at 3, 6, and 12 months postoperatively. Two patients (Nos. 11 and 13) who died from cancer were not evaluated at 12 months postoperatively.

2.2 Titanium vocal fold medializing implant for type 1 thyroplasty

A specially devised titanium vocal fold medializing implant for type 1 thyroplasty invented by KM was used for this study (Patent number: WO/2015/111340). Briefly, this titanium plate is composed of a fixing part for fixing at one end thereof to the thyroid cartilage, and a main body part capable of bending along bend lines drawn in two locations as shown in Figure 1. This titanium plate could be molded in these lines easily by surgical tools such as a hemostat. The plate could be tilted downward by 15°, when the implant was bended along the line applied a 105°/75° in the plate, so that this tilt counteracted the upward force of the plate tip, resulting in that the implant could be pushed parallel to the vocal folds as described in our previous literature. Thus, arbitrary bending this titanium plate enable us to adjust the degree of medialization of the paralyzed vocal fold.

2.3 Operative procedure

All surgeries were performed under local anesthesia combined with intravenous sedation using propofol. The same surgeons (YI and YC) performed the surgery in all 16 patients. First, arytenoid adduction (AA) was performed as described previously. The external vocal fold medialization by type 1 thyroplasty was then performed as described in our previous literature.11 The external vocal fold medialization...
The distance from the midline of the anterior thyroid cartilage border line to the anterior end of the thyroplasty window was 5–6 mm on the line corresponding to the horizontal level of the vocal folds, and the 5 × 10 mm of the thyroplasty window was designed. An arranged titanium plate with appropriate size was then temporarily implanted after the cartilage fenestration with preserving of the inner perichondrium. The intraoperative assessment of glottal closure was finally adjusted using flexible videolaryngoscopy to rearrange the titanium plate with optimal size, and patient’s own subjective and surgeons’ objective auditory evaluations of his/her voice throughout the rearrangement of the size and placing of the titanium plate. Before the final adjustment of glottal closure, the patient was temporally awoken by the anesthetist to become able to phonate according to the instruction of the surgeons.

2.4 | Maximum phonation time (MPT) assessment

Improvement of MPT was the primary endpoint of this study. MPT of a sustained Japanese vowel /a/ following deep breath was evaluated preoperatively, at 3, 6, and 12 months postoperatively. Patients with MPT over 15 seconds at all postoperative time points were considered as successful.

2.5 | Auditory perceptual assessment

The patients were instructed to read a standardized passage and sustain Japanese the vowels /a/, /e/, /ɪ/, /o/, and /u/ at a comfortable pitch and intensity levels, and evaluated according to the GRBAS scale in which the following parameters were rated on a four-point scale: 0 (normal) to 4 (severe): the overall grade (G) of dysphonia, roughness (R), breathiness (B), asthenia (A), and straining (S). The evaluation was conducted by speech therapists (YI) and otolaryngologists using our routine method according to the guideline of the Japan Society of Logopedics and Phoniatrics 2018.

2.6 | Aerodynamic examination

Aerodynamic examination was performed using a phonation analyzer (PA-1000; Minato, Osaka, Japan). For assessing the aerodynamic data, each patient was required to phonate a sustained Japanese vowel /a/ into a cylindrical mouthpiece, and the mean flow rate (MFR) was obtained together with voice efficiency.

2.7 | Acoustic analyses

Acoustic evaluation was also performed pre- and postoperatively. A relatively stable 5-second duration segment of each voice samples were recorded using a condenser microphone (Audio Technica: ATM31a), directly stored in a personal computer through an audio-interface (Edirol: UA-25) at the rate of 24 bit/s with sampling frequency of 96 Hz, and then analyzed using the multi-dimensional voice program in a computerized
speech laboratory system (CSL4500, Kay-Pentax, Tokyo, Japan) to determine the following acoustic measurements: percentage shimmer, percentage jitter, the harmonics-to-noise ratio (HNR: the ratio of energy in the harmonic vs the noise components), and the fundamental frequency (F0). In 8 patients (Nos. 1, 3, 8, 10, 13, 14, 15, 16) presenting preoperative MPT of less than 5 seconds, the acoustic analyses were not performed.

2.8 Voice specific patient-reported outcome measures and other instrumental measures

The voice handicap index (VHI)\textsuperscript{14} and voice-related quality of life (VRQOL)\textsuperscript{15} were administered pre- and postoperatively to quantify the psychosocial consequences of vocal handicap and the voice-related quality of life. In addition, all patient routinely received fibercopic videolaryngostroboscopy pre- and postoperatively. The examination was performed using a flexible fibercopy (Fujifilm Corp., Tokyo, Japan) and a light source (Nagashima Medical Instruments, Tokyo, Japan). All patients also underwent computed tomography at 6 months post-operatively to evaluate the position of the titanium plate in the larynx after thyroplasty.

2.9 Statistical analysis

Significant differences between the pre- and postoperative parameters were analyzed with the repeated measure ANOVA test. Statistical analysis was performed using the JMP software (Version 12.2.0, SAS)
Institute, Inc., Cary, NC). $P < .05$ was considered statistically significant.

### RESULTS

#### 3.1 Patient characteristics

The clinical characteristics of 16 patients in this study are summarized in Table 1. The median age of patients was 63.5 years (range, 28-77 years), and 11 patients (68.8%) were male. This series included 14 left and 2 right UVFP. The median duration time from onset of UVFP to type 1 thyroplasty combined with AA was 17 months. The median preoperative MPT was 4.99 seconds. No major postoperative complications such as severe postoperative hemorrhage, surgical site infection, or postoperative laryngeal edema necessitating tracheotomy, were observed in this series. Appropriate location of titanium vocal fold medializing implant in each patient was observed in CT image examination performed at 6 months postoperatively (Figure 2). No late adverse events related to the surgery such as foreign body concerns, or extrusion, were not observed 12 months postoperatively. These results suggested that all patients presented no late complication associated with this surgical approach.

#### 3.2 Functional outcome of vocal parameters after type 1 thyroplasty

Results of auditory perceptual assessment, aerodynamic examination and QOL compared preoperatively, at 3, 6, and 12 months postoperatively were summarized in Table 2. The MPT improved immediately from 5.63 (preoperative mean) to 20.52 at 3 months postoperatively, and the improvement in MPT by surgery was observed over the 12-month postoperative period ($P < .001$) as shown in Figure 3A. The improvement in MFR was also observed from 731.50 mL/sec (preoperatively) to 165.65 3 months postoperatively and maintained over the 12-month postoperative period as shown in Figure 3B ($P < .001$).

In addition, among GRBAS score, G, R, and B scores improved significantly over the 12-month postoperative period ($P < .001$, respectively, Figure 3C). Furthermore, the improvements in the VHI and the V-RQOL score were gradually observed over the 12-month postoperative period as shown in Table 2, and the difference between preoperatively and postoperatively showed significant ($P < .001$ and $P < .001$, respectively, Figure 3D,E).

Results of acoustic examination on eight cases out of the 16 compared preoperatively, and at 3, 6, and 12 months postoperatively were summarized in Table 3. On the remaining eight cases, the preoperative acoustic examination was not available due to severe hoarseness. The mean Jitter improved immediately from 5.08 (preoperatively) to 2.42 at 3 months postoperatively, and the improvement of the Jitter by surgery was observed over the 12-month postoperative, however, there was no significant difference ($P = .205$, Figure 3F). The improvements in the Shimmer were gradually observed
over the 12-month postoperative period, however, no significant difference was found using ANOVA ($P = .710$, Figure 3G). Lastly, there were no significant differences of mean NHR and F0 over the 12-month postoperative period ($P = .846$ and $P = .312$, respectively, Figure 3H, I).

Overall, type 1 thyroplasty using our novel TMLI combined with AA presented significant improvement of the subjective and objective functional voice outcomes of patients with UVFP without any complication associated with this surgical approach over the long-term postoperative period in this study.

4 | DISCUSSION

In this study, long-term good treatment outcome of type 1 thyroplasty using our novel TMLI for UVFP combined with AA, including significant improvements of MPT, MFR, GRBAS, the VHI and the V-RQOL score, was observed over the 12-month postoperative period as a prospective single arm study. Interestingly, our results showed that the voice-related quality of life was improved gradually over the 12-months, suggesting the satisfaction of patients with UVFP require a relatively long span of time after type 1 thyroplasty with AA.

The implants for type 1 thyroplasty to medialize the paralyzed vocal fold adequately are generally required to possess the following principal characteristics, (1) the material used to make the implant should have tissue affinity and homeostasis, (2) the manipulation of the implant should be easy in the surgical field, (3) the implant should have sufficient strength and stability in the fixed position, (4) the implant should be effective for voice improvement, and (5) surgical revisions should be possible after the initial implantation.

In the present study, the short and long-term significant improvements of MPT, MFR, GRBAS, the VHI and the V-RQOL score were observed. In particular, the improvements in MPT in the current study might make it difficult to examine the independence applicability of type 1 thyroplasty using TMLI as treatment outcomes. Although this study had the above-mentioned limitations, our findings on long-term follow-up may provide impact on usability of our novel TMLI for the treatment of patients with UVFP.

5 | CONCLUSION

We here present the long-term treatment outcome of type 1 thyroplasty using TMLI combined with AA for UVFP as single-arm interventional study in a single institution. We observed that type 1 thyroplasty using TMLI with arytenoid adduction significantly improved MPT, MFR, GRBAS, the VHI, and the V-RQOL score without any complication associated with this surgical approach over the long-term postoperative period in this study. To reveal the significance of our novel titanium implant for the
treatment on patients with UVFP, further multi-institutional study would be required.

ACKNOWLEDGEMENT
Yokohama City University Hospital advanced medical treatment supporting system covered the surgical and hospitalization fees of the study patients (approval No. 28-112).

CONFLICT OF INTEREST
The authors declare no conflicts of interests.

ORCID
Daisuke Sano https://orcid.org/0000-0002-7686-4724
Koji Matsushima https://orcid.org/0000-0002-6739-3289

REFERENCES
1. Isshiki N, Morita H, Okamura H, Hiramoto M. Thyroplasty as a new phonosurgical technique. Acta Otolaryngol. 1974;78: 451-457.
2. Young VN, Zullo TG, Rosen CA. Analysis of laryngeal framework surgery: 10-year follow-up to a national survey. Laryngoscope. 2010;120: 1602-1608.
3. Watanabe K, Hirano A, Honkura Y, Kashima K, Shirakura M, Katori Y. Complications of using Gore-Tex in medialization laryngoplasty: case series and literature review. Eur Arch Otorhinolaryngol. 2019;276: 255-261.
4. Sims JR, Lalich IJ, Ekborn DC. Displacement of residual gore-tex thyroplasty implant presenting as a true vocal fold mass. Otolaryngol Head Neck Surg. 2014;150:1090-1091.
5. Friedrich G. Titanium vocal fold medializing implant: introducing a novel implant system for external vocal fold medialization. Ann Otol Rhinol Laryngol. 1999;108:79-86.
6. Suzuki R, Frangos JA. Inhibition of inflammatory species by titanium surfaces. Clin Orthop Relat Res. 2000;372:280-289.
7. Schneider-Stickler B, Gaechter J, Bigenzahn W. Long-term results after external vocal fold medialization thyroplasty with titanium vocal fold medialization implant (TVFMI). Eur Arch Otorhinolaryngol. 2013; 270:1689-1694.
8. Sanuki T, Yumoto E. Long-term evaluation of type 2 Thyroplasty with titanium bridges for adductor spasmodic dysphonia. Otolaryngol Head Neck Surg. 2017;157:80-84.
9. Sanuki T, Yumoto E, Kodama N, Minoda R, Kumai Y. Long-term voice handicap index after type II thyroplasty using titanium bridges for adductor spasmodic dysphonia. Auris Nasus Larynx. 2014;41: 285-289.
10. Matsushima K. Investigation of type I thyroplasty using titanium implant. Nihon Jibiinkoka Gakkai Kaiho. 2015;118:1027-1036.
11. Matsushima K. The all muscles preserved method in arytenoid adduction. Clin Otolaryngol. 2019;44:1186-1189.
12. Matsushima K. Type I thyroplasty using a titanium implant combined with modified arytenoid adduction. Laryngoscope. 2020; https://onlinelibrary.wiley.com/doi/10.1002/lary.28865.
13. Umeno H, Hyodo M, Haji T, et al. A summary of the clinical practice guideline for the diagnosis and management of voice disorders, 2018 in Japan. Auris Nasus Larynx. 2020;47:7-17.
14. Jacobson BH, Johnson A, al GC. The voice handicap index (VHI): development and validation. Am J Speech Lang Pathol. 1997;6: 66-70.
15. Hogikyan ND, Sethuraman G. Validation of an instrument to measure voice-related quality of life (V-RQOL). J Voice. 1999;13:557-569.
16. Laccourreye O, El Sharkawy L, Holsinger FC, Hans S, Menard M, Brasnu D. Thyroplasty type I with Montgomery implant among native French language speakers with unilateral laryngeal nerve paralysis. Laryngoscope. 2005;115:1411-1417.
17. Isshiki N, Tanabe M, Sawada M. Arytenoid adduction for unilateral vocal cord paralysis. Arch Otolaryngol. 1978;104:555-558.